@cookercooker not yet, Elahere is her next line (3rd line), her FRa expression is 75%, which means it has very good chance or working, overall survivability on Elahere is about 17 months.

@cookercooker Enhertu might be candidate if: Confirm HER2 status of the tumor (by IHC/ISH) — ideally centrally reviewed; look for IHC 3+ (or 2+ with ISH amplification) if considering benefit from T-DXd. Data suggest the best responses in IHC 3+ tumors.